FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Norio Yasui-Furukori

Research Profile

Disorders

Schizophrenia

Chemicals & Drugs

Concepts & Ideas

Physiology

Procedures

Geographic Areas

Japan

Co-author Network

Publications

TOP 3
Norio Sugawara; Norio Yasui-Furukori; Hanako Furukori; Shuhei Kudo; Taku Nakagami; Manabu Saito; Yasushi Sato; Sunao Kaneko
Body mass index and quality of life among outpatients with schizophrenia in Japan.
Norio Yasui-Furukori; Kojiro Hashimoto; Kazutoshi Kubo; Tetsu Tomita
Interaction between paliperidone extended release and TS-1(®), an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient.
Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Sunao Kaneko
The CLOCK C3111T polymorphism is associated with reward dependence in healthy Japanese subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Norio Yasui-Furukori (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Norio Sugawara; Norio Yasui-Furukori; Hanako Furukori; Shuhei Kudo; Taku Nakagami; Manabu Saito; Yasushi Sato; Sunao Kaneko
Body mass index and quality of life among outpatients with schizophrenia in Japan.
BMC psychiatry 2013;13():108.
2013: Norio Yasui-Furukori; Kojiro Hashimoto; Kazutoshi Kubo; Tetsu Tomita
Interaction between paliperidone extended release and TS-1(®), an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient.
Neuropsychiatric disease and treatment 2013;9():317-20.
2013: Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Sunao Kaneko
The CLOCK C3111T polymorphism is associated with reward dependence in healthy Japanese subjects.
Neuropsychobiology 2013;67(1):1-5.
2013: Hiroyuki Kusuhara; Masatomo Miura; Yumiko Akamine; Shinya Fukizawa; Kazuaki Ikejiri; Kayoko Kanamitsu; Tsukasa Uno; Norio Yasui-Furukori; Miyu Yokochi; Kenta Yoshida; Yuichi Sugiyama
Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(1):206-13.
2012: Norio Sugawara; Ippei Takahashi; Osamu Tanaka; Takashi Umeda; Norio Yasui-Furukori; Kaori Iwane; Sunao Kaneko; Masashi Matsuzaka; Giro Sasaki; Shigeyuki Nakaji
Coping behaviors in relation to depressive symptoms and suicidal ideation among middle-aged workers in Japan.
Journal of affective disorders 2012;142(1-3):264-8.
2012: Yumiko Akamine; Ichiro Ieiri; Norio Yasui-Furukori; Tsukasa Uno
Psychotropic drug-drug interactions involving P-glycoprotein.
CNS drugs 2012;26(11):959-73.
2012: Norio Sugawara; Ippei Takahashi; Shoko Tsuchimine; Norio Yasui-Furukori; Kazuma Danjo; Akira Fujii; Ayako Kaneda; Masashi Matsuzaka; Yasushi Sato; Sunao Kaneko
Factor structure of the Liebowitz Social Anxiety Scale in community-dwelling subjects in Japan.
Psychiatry and clinical neurosciences 2012;66(6):525-8.
2012: Shoko Tsuchimine; Norio Yasui-Furukori; Taku Nakagami; Yasushi Sato; Sunao Kaneko
DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.
Journal of clinical psychopharmacology 2012;32(5):724-6.
2012: Shoko Tsuchimine; Norio Yasui-Furukori; Shuichi Yoshida; Ayako Kaneda; Kunihiro Sasaki; Norio Sugawara; Sunao Kaneko
Association between the dopamine D2 receptor (DRD2) polymorphism and the personality traits of healthy Japanese participants.
Progress in neuro-psychopharmacology & biological psychiatry 2012;38(2):190-3.
2012: Hideo Shiohira; Tomonori Tateishi; Satoshi Yamada; Norio Yasui-Furukori; Yumiko Akamine; Tsukasa Uno
Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.
Pharmaceutical research 2012;29(8):2310-6.
2012: Norio Yasui-Furukori; Ayako Kaneda; Norio Sugawara; Tetsu Tomita; Sunao Kaneko
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Journal of psychopharmacology (Oxford, England) 2012;26(6):806-12.
2012: Junji Saruwatari; Ayaka Takashima; Yumiko Akamine; Sunao Kaneko; Takenori Niioka; Norio Yasui-Furukori; Tsukasa Uno
Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
Journal of clinical psychopharmacology 2012;32(2):195-9.
2012: Junji Saruwatari; Norio Yasui-Furukori; Shuichi Yoshida; Shiho Yoshida; Yuki Yoshimori; Mariko Deguchi; Takateru Ishitsu; Sunao Kaneko; Madoka Noai; Naoki Ogusu; Kentaro Oniki; Kazuko Nakagawa
Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases.
Epilepsy research 2012;99(1-2):183-6.
2012: Yumiko Akamine; Midori Kojima; Masatomo Miura; Norio Yasui-Furukori; Tsukasa Uno
Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
British journal of clinical pharmacology 2012;73(3):478-81.
2012: Tetsu Tomita; Norio Yasui-Furukori; Ayako Kaneda; Taku Nakagami; Sunao Kaneko
The association between sunshine duration and paroxetine response time in patients with major depressive disorder.
Journal of affective disorders 2012;136(3):1067-71.
2012: Norio Sugawara; Ippei Takahashi; Takashi Umeda; Norio Yasui-Furukori; Kazuma Danjo; Sunao Kaneko; Masashi Matsuzaka; Giro Sasaki; Shigeyuki Nakaji
Relationships between suicidal ideation and the dimensions of depressive symptoms among middle-aged population in Japan.
Journal of affective disorders 2012;136(3):819-23.
2012: Norio Sugawara; Ippei Takahashi; Shoko Tsuchimine; Koji Tsuruga; Norio Yasui-Furukori; Kaori Iwane; Ayako Kaneda; Noriyuki Okubo; Sunao Kaneko
No association between dietary patterns and depressive symptoms among a community-dwelling population in Japan.
Annals of general psychiatry 2012;11(1):24.
2012: Norio Yasui-Furukori
Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Drug design, development and therapy 2012;6():107-15.
2012: Norio Sugawara; Ippei Takahashi; Shoko Tsuchimine; Norio Yasui-Furukori; Akira Fujii; Masashi Matsuzaka; Manabu Saito; Yasushi Sato; Sunao Kaneko
Body composition in patients with schizophrenia: Comparison with healthy controls.
Annals of general psychiatry 2012;11(1):11.
2012: Norio Sugawara; Ippei Takahashi; Shoko Tsuchimine; Takashi Umeda; Norio Yasui-Furukori; Kazuma Danjo; Akira Fujii; Hanako Furukori; Masashi Matsuzaka; Manabu Saito; Yasushi Sato; Sunao Kaneko
Effect of age and disease on bone mass in Japanese patients with schizophrenia.
Annals of general psychiatry 2012;11():5.
2012: Norio Yasui-Furukori; Akira Fujii; Kojiro Hashimoto; Manabu Saito; Norio Sugawara; Shoko Tsuchimine; Sunao Kaneko
No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics.
Human psychopharmacology 2012;27(1):82-9.
2011: Ayako Kaneda; Taku Nakagami; Yasushi Sato; Norio Yasui-Furukori; Sunao Kaneko
The influence of personality factors on paroxetine response time in patients with major depression.
Journal of affective disorders 2011;135(1-3):321-5.
2011: Yasuhiro Kaneda; Yuko Higuchi; Toru Ito; Tomiki Sumiyoshi; Michio Suzuki; Yoshinori Ueoka; Norio Yasui-Furukori; Tetsuro Ohmori
[Schizophrenia Cognition Rating Scale Japanese version (SCoRS-J) as a co-primary measure assessing cognitive function in schizophrenia].
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 2011;31(5-6):259-62.
2011: Norio Yasui-Furukori; Sunao Kaneko
The efficacy of low-dose aripiprazole treatment for trichotillomania.
Clinical neuropharmacology 2011;34(6):258-9.
2011: Norio Yasui-Furukori; Akira Fujii; Taku Nakagami; Manabu Saito; Norio Sugawara; Shoko Tsuchimine; Sunao Kaneko
Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Journal of clinical psychopharmacology 2011;31(5):633-7.
2011: Rieko Kitagawa; Takao Tsushima; Norio Yasui-Furukori; Sunao Kaneko; Ikuo Fukuda
Depression increases the length of hospitalization for patients undergoing thoracic surgery: a preliminary study.
Psychosomatics 2011;52(5):428-32.
2011: Hideo Shiohira; Tomonori Tateishi; Norio Yasui-Furukori; Tsukasa Uno
Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(24):2465-70.
2011: Norio Yasui-Furukori; Sunao Kaneko
Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
Psychiatry and clinical neurosciences 2011;65(4):384-5.
2011: Norio Yasui-Furukori; Kaori Yoshizawa; Akira Fujii; Yoshimasa Inoue; Taku Nakagami; Yasushi Sato; Tetsu Tomita; Shoko Tsuchimine; Sunao Kaneko
Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder.
Human psychopharmacology 2011;26(3):194-200.
2011: Norio Sugawara; Norio Yasui-Furukori; Takashi Umeda; Ayako Kaneda; Yasushi Sato; Ippei Takahashi; Masashi Matsuzaka; Kazuma Danjo; Shigeyuki Nakaji; Sunao Kaneko
Ankle brachial pressure index as a marker of apathy in a community-dwelling population.
International journal of geriatric psychiatry 2011;26(4):409-14.
2011: Chikako Ohta; Norio Yasui-Furukori; Hanako Furukori; Shoko Tsuchimine; Manabu Saito; Taku Nakagami; Kaori Yoshizawa; Sunao Kaneko
The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Progress in neuro-psychopharmacology & biological psychiatry 2011;35(2):573-6.
2011: Norio Sugawara; Norio Yasui-Furukori; Giro Sasaki; Takashi Umeda; Ippei Takahashi; Kazuma Danjo; Masashi Matsuzaka; Sunao Kaneko; Shigeyuki Nakaji
Assessment of the Center for Epidemiological Studies Depression Scale factor structure among middle-aged workers in Japan.
Psychiatry and clinical neurosciences 2011;65(1):109-11.
2011: Norio Sugawara; Takashi Umeda; Norio Yasui-Furukori; Seiji Kakehata; Shigeyuki Nakaji; Atsushi Namba; Akira Sasaki; Hideichi Shinkawa; Sunao Kaneko
Hearing impairment and cognitive function among a community-dwelling population in Japan.
Annals of general psychiatry 2011;10(1):27.
2011: Norio Sugawara; Hakuei Yamashita; Norio Yasui-Furukori; Hanako Furukori; Mitsunori Hatakeyama; Ikuko Kishida; Taku Nakagami; Manabu Saito; Yasushi Sato; Sunao Kaneko
Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia.
Annals of general psychiatry 2011;10():21.
2011: Gen Odagiri; Hisao Saitoh; Norio Sugawara; Ippei Takahashi; Takashi Umeda; Norio Yasui-Furukori; Atsuhiro Kikuchi; Sunao Kaneko
Cognitive function among hemodialysis patients in Japan.
Annals of general psychiatry 2011;10():20.
2010: Yukako Nakamura; Yoshihito Ito; Branko Aleksic; Itaru Kushima; Norio Yasui-Furukori; Toshiya INADA; Yutaka Ono; Norio Ozaki
Influence of HTR2A polymorphisms and parental rearing on personality traits in healthy Japanese subjects.
Journal of human genetics 2010;55(12):838-41.
2010: Yumiko Akamine; Norio Yasui-Furukori; Midori Kojima; Yoshimasa Inoue; Tsukasa Uno
A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies.
Journal of separation science 2010;33(21):3292-8.
2010: Norio Sugawara; Norio Yasui-Furukori; Yasushi Sato; Takashi Umeda; Ikuko Kishida; Hakuei Yamashita; Manabu Saito; Hanako Furukori; Taku Nakagami; Mitsunori Hatakeyama; Shigeyuki Nakaji; Sunao Kaneko
Prevalence of metabolic syndrome among patients with schizophrenia in Japan.
Schizophrenia research 2010;123(2-3):244-50.
2010: Yumiko Akamine; Masatomo Miura; Satoko Sunagawa; Hideaki Kagaya; Norio Yasui-Furukori; Tsukasa Uno
Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(11):782-9.
2010: Yasushi Sato; Norio Yasui-Furukori; Hanako Furukori; Manabu Saito; Taku Nakagami; Sunao Kaneko
A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.
Experimental and clinical psychopharmacology 2010;18(5):445-50.
2010: Norio Yasui-Furukori; Hanako Furukori; Norio Sugawara; Akira Fujii; Sunao Kaneko
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Journal of clinical psychopharmacology 2010;30(5):596-9.
2010: Ayako Kaneda; Norio Yasui-Furukori; Takashi Umeda; Norio Sugawara; Shoko Tsuchimine; Manabu Saito; Yasushi Sato; Hanako Furukori; Ippei Takahashi; Shigeyuki Nakaji; Sunao Kaneko
Comparing the influences of age and disease on distortion in the clock drawing test in Japanese patients with schizophrenia.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2010;18(10):908-16.
2010: Junji Saruwatari; Norio Yasui-Furukori; Yoshimasa Inoue; Sunao Kaneko
Effect of dose timing in relation to food intake on systemic exposure to blonanserin.
European journal of clinical pharmacology 2010;66(9):899-902.
2010: Norio Sugawara; Norio Yasui-Furukori; Takashi Umeda; Yasushi Sato; Ayako Kaneda; Shoko Tsuchimine; Manabu Saito; Shigeyuki Nakaji; Sunao Kaneko
Clock drawing performance in a community-dwelling population: Normative data for Japanese subjects.
Aging & mental health 2010;14(5):587-92.
2010: Norio Yasui-Furukori; Manabu Saito; Taku Nakagami; Hanako Furukori; Akihito Suzuki; Tsuyoshi Kondo; Sunao Kaneko
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Journal of psychopharmacology (Oxford, England) 2010;24(7):987-94.
2010: Norio Yasui-Furukori; Manabu Saito; Taku Nakagami; Norio Sugawara; Yasushi Sato; Shoko Tsuchimine; Hanako Furukori; Sunao Kaneko
Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(3):537-40.
2010: Ayako Kaneda; Norio Yasui-Furukori; Manabu Saito; Norio Sugawara; Taku Nakagami; Hanako Furukori; Sunao Kaneko
Characteristics of the tree-drawing test in chronic schizophrenia.
Psychiatry and clinical neurosciences 2010;64(2):141-8.
2010: Norio Yasui-Furukori; Hanako Furukori; Norio Sugawara; Shoko Tsuchimine; Akira Fujii; Yoshimasa Inoue; Sunao Kaneko
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
Human psychopharmacology 2010;25(3):236-42.
2010: Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Manabu Saito; Taku Nakagami; Norio Sugawara; Sunao Kaneko
No association between polymorphism in tyrosine hydroxylase and personality traits in healthy Japanese subjects.
Psychiatry and clinical neurosciences 2010;64(2):196-8.
2010: Akira Fujii; Norio Yasui-Furukori; Norio Sugawara; Yasushi Sato; Taku Nakagami; Manabu Saito; Sunao Kaneko
Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics.
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(2):288-93.
2010: Norio Sugawara; Norio Yasui-Furukori; Takashi Umeda; Ayako Kaneda; Yasushi Sato; Ippei Takahashi; Masashi Matsuzaka; Kazuma Danjo; Shigeyuki Nakaji; Sunao Kaneko
Comparison of ankle-brachial pressure index and pulse wave velocity as markers of cognitive function in a community-dwelling population.
BMC psychiatry 2010;10():46.
2009: Satoshi Yamada; Norio Yasui-Furukori; Yumiko Akamine; Sunao Kaneko; Tsukasa Uno
Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Therapeutic drug monitoring 2009;31(6):764-8.
2009: Goyo Nagai; Shingo Ono; Norio Yasui-Furukori; Akifumi Nakamura; Kazuo Mihara; Tsuyoshi Kondo
Formulations of valproate alter valproate metabolism: a single oral dose kinetic study.
Therapeutic drug monitoring 2009;31(5):592-6.
2009: Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Manabu Saito; Norio Sugawara; Sunao Kaneko
Minor genetic variants of the dopamine D4 receptor (DRD4) polymorphism are associated with novelty seeking in healthy Japanese subjects.
Progress in neuro-psychopharmacology & biological psychiatry 2009;33(7):1232-5.
2009: Mao Mao; Alice Matimba; Maria Gabriella Scordo; Arzu Gunes; Hakan Zengil; Norio Yasui-Furukori; Collen M Masimirembwa; Marja-Liisa Dahl
Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis.
Pharmacogenomics 2009;10(9):1447-55.
2009: Norio Yasui-Furukori; Masato Kusunoki; Sunao Kaneko
Hallucinations associated with modafinil treatment for narcolepsy.
Journal of clinical psychopharmacology 2009;29(4):408.
2009: Norio Sugawara; Norio Yasui-Furukori; Sunao Kaneko
Improvement of tardive dyskinesia following zopiclone treatment.
Progress in neuro-psychopharmacology & biological psychiatry 2009;33(4):727-8.
2009: Yasushi Sato; Norio Yasui-Furukori; Taku Nakagami; Manabu Saito; Sunao Kaneko
Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
Progress in neuro-psychopharmacology & biological psychiatry 2009;33(3):416-8.
2009: Atsuhiro Kikuchi; Norio Yasui-Furukori; Akira Fujii; Hiroshi Katagai; Sunao Kaneko
Identification of predictors of post-ictal delirium after electroconvulsive therapy.
Psychiatry and clinical neurosciences 2009;63(2):180-5.
2009: Hiroshi Katagai; Norio Yasui-Furukori; Atsuhiro Kikuchi; Sunao Kaneko
Bemegride lengthens seizure duration during electric convulsive therapy in a schizophrenic patient with increased seizure threshold.
The journal of ECT 2009;25(1):61-3.
2009: Akira Fujii; Norio Yasui-Furukori; Taku Nakagami; Takenori Niioka; Manabu Saito; Yasushi Sato; Sunao Kaneko
Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations.
Drug design, development and therapy 2009;2():139-44.
2009: Norio Yasui-Furukori; Yasushi Sato; Hanako Furukori; Manabu Saito; Taku Nakagami; Sunao Kaneko
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
The Journal of clinical psychiatry 2009;70(1):95-100.
2008: Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Manabu Saito; Taku Nakagami; Kimihiko Sato; Sunao Kaneko
Association between monoamine oxidase A (MAOA) and personality traits in Japanese individuals.
Progress in neuro-psychopharmacology & biological psychiatry 2008;32(8):1932-5.
2008: Norio Yasui-Furukori; Manabu Saito; Shoko Tsuchimine; Taku Nakagami; Yasushi Sato; Norio Sugawara; Sunao Kaneko
Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Progress in neuro-psychopharmacology & biological psychiatry 2008;32(6):1491-5.
2008: Takenori Niioka; Masatomo Miura; Tsukasa Uno; Norio Yasui-Furukori; Makoto Hayakari; Tomonori Tateishi; Toshio Suzuki
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
European journal of clinical pharmacology 2008;64(5):503-9.
2008: Yasushi Sato; Norio Yasui-Furukori; Sunao Kaneko; Takako Moriyama
New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone.
Progress in neuro-psychopharmacology & biological psychiatry 2008;32(2):577-8.
2007: Hiroshi Katagai; Norio Yasui-Furukori; Atsuhiro Kikuchi; Sunao Kaneko
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Psychiatry and clinical neurosciences 2007;61(5):568-70.
2007: Norio Yasui-Furukori; Ayako Kaneda; Kumiko Iwashima; Manabu Saito; Taku Nakagami; Shoko Tsuchimine; Sunao Kaneko
Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2007;144B(6):724-7.
2007: Norio Yasui-Furukori; Shoko Tsuchimine; Manabu Saito; Taku Nakagami; Yasushi Sato; Sunao Kaneko
Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.
Progress in neuro-psychopharmacology & biological psychiatry 2007;31(6):1230-4.
2007: Kumiko Iwashima; Norio Yasui-Furukori; Ayako Kaneda; Manabu Saito; Taku Nakagami; Yasushi Sato; Sunao Kaneko
No association between CYP2D6 polymorphisms and personality trait in Japanese.
British journal of clinical pharmacology 2007;64(1):96-9.
2007: Hitoshi Osaka; Ikuo Ogiwara; Emi Mazaki; Nami Okamura; Sumimasa Yamashita; Mizue Iai; Michiko Yamada; Kenji Kurosawa; Hiroko Iwamoto; Norio Yasui-Furukori; Sunao Kaneko; Tateki Fujiwara; Yushi Inoue; Kazuhiro Yamakawa
Patients with a sodium channel alpha 1 gene mutation show wide phenotypic variation.
Epilepsy research 2007;75(1):46-51.
2007: Norio Yasui-Furukori; Manabu Saito; Taku Nakagami; Takenori Niioka; Yasushi Sato; Akira Fujii; Sunao Kaneko
Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
Psychiatry and clinical neurosciences 2007;61(3):308-12.
2007: Baljinder Singh; Monteil Arnaud; Isabelle Bidaud; Yoshihisa Sugimoto; Toshimitsu Suzuki; Shin-ichiro Hamano; Hirokazu Oguni; Makiko Osawa; Maria E Alonso; Antonio V Delgado-Escueta; Yushi Inoue; Norio Yasui-Furukori; Sunao Kaneko; Philippe Lory; Kazuhiro Yamakawa
Mutational analysis of CACNA1G in idiopathic generalized epilepsy. Mutation in brief #962. Online.
Human mutation 2007;28(5):524-5.
2007: Noboru Sakumoto; Tsuyoshi Kondo; Kazuo Mihara; Akihito Suzuki; Norio Yasui-Furukori
Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Psychiatry and clinical neurosciences 2007;61(2):174-80.
2007: Takenori Niioka; Tsukasa Uno; Norio Yasui-Furukori; Takenori Takahata; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi
Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Cancer chemotherapy and pharmacology 2007;59(5):575-80.
2007: Norio Yasui-Furukori; Manabu Saito; Takenori Niioka; Yoshimasa Inoue; Yasushi Sato; Sunao Kaneko
Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.
Therapeutic drug monitoring 2007;29(1):45-8.
2007: Tsukasa Uno; Takenori Niioka; Makoto Hayakari; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
European journal of clinical pharmacology 2007;63(2):143-9.
2007: Norio Yasui-Furukori; Manabu Saito; Yoshimasa Inoue; Takenori Niioka; Yasushi Sato; Shoko Tsuchimine; Sunao Kaneko
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
European journal of clinical pharmacology 2007;63(1):51-6.
2006: Takenori Niioka; Tsukasa Uno; Norio Yasui-Furukori; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi
Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.
European journal of clinical pharmacology 2006;62(10):855-61.
2006: Mikiko Shimizu; Tsukasa Uno; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
European journal of clinical pharmacology 2006;62(8):597-603.
2006: Takenori Niioka; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Sunao Kaneko; Tomonori Tateishi
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Therapeutic drug monitoring 2006;28(3):321-5.
2006: Takashi Fukasawa; Norio Yasui-Furukori; Akihito Suzuki; Genki Ishii; Yoshimasa Inoue; Tomonori Tateishi; Koichi Otani
Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug.
Therapeutic drug monitoring 2006;28(3):308-11.
2006: Yukihiro Ujiie; Takashi Fukasawa; Norio Yasui-Furukori; Akihito Suzuki; Tomonori Tateishi; Koichi Otani
Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.
Therapeutic drug monitoring 2006;28(3):299-302.
2006: Tsukasa Uno; Norio Yasui-Furukori
Effect of grapefruit juice in relation to human pharmacokinetic study.
Current clinical pharmacology 2006;1(2):157-61.
2006: Norio Yasui-Furukori; Sunao Kaneko
Digitalis intoxication induced by paroxetine co-administration.
Lancet 2006;367(9512):788.
2006: Masatomo Miura; Hideaki Kagaya; Hitoshi Tada; Tsukasa Uno; Norio Yasui-Furukori; Tomonori Tateishi; Toshio Suzuki
Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
British journal of clinical pharmacology 2006;61(3):315-20.
2006: Tsukasa Uno; Mikiko Shimizu; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
British journal of clinical pharmacology 2006;61(3):309-14.
2006: Norio Yasui-Furukori; Manabu Saito; Taku Nakagami; Ayako Kaneda; Tomonori Tateishi; Sunao Kaneko
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
Progress in neuro-psychopharmacology & biological psychiatry 2006;30(2):286-91.
2006: Masatomo Miura; Hideaki Kagaya; Hitoshi Tada; Tsukasa Uno; Norio Yasui-Furukori; Tomonori Tateishi; Toshio Suzuki
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Xenobiotica; the fate of foreign compounds in biological systems 2006;36(1):95-102.
2005: Manabu Saito; Norio Yasui-Furukori; Taku Nakagami; Hanako Furukori; Sunao Kaneko
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
Journal of clinical psychopharmacology 2005;25(6):527-32.
2005: Takashi Fukasawa; Norio Yasui-Furukori; Akihito Suzuki; Y Inoue; Tomonori Tateishi; Koichi Otani
Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.
European journal of clinical pharmacology 2005;61(11):791-5.
2005: Tsukasa Uno; Norio Yasui-Furukori; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi
Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;824(1-2):238-43.
2005: Takaki Tokairin; Takashi Fukasawa; Norio Yasui-Furukori; Toshiaki Aoshima; Akihito Suzuki; Yoshimasa Inoue; Tomonori Tateishi; Koichi Otani
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.
British journal of clinical pharmacology 2005;60(2):172-5.
2005: Taku Nakagami; Norio Yasui-Furukori; Manabu Saito; Tomonori Tateishi; Sunao Kaneo
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Clinical pharmacology and therapeutics 2005;78(1):43-51.
2005: Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
British journal of clinical pharmacology 2005;60(1):61-8.
2005: Manabu Saito; Norio Yasui-Furukori; Sunao Kaneko
[Clinical pharmacogenetics in the treatment of schizophrenia].
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 2005;25(3):129-35.
2005: Toshiki Kunii; Takashi Fukasawa; Norio Yasui-Furukori; Toshiaki Aoshima; Akihito Suzuki; Tomonori Tateishi; Yoshimasa Inoue; Koichi Otani
Interaction study between enoxacin and fluvoxamine.
Therapeutic drug monitoring 2005;27(3):349-53.
2005: Tsukasa Uno; Norio Yasui-Furukori; Takenori Takahata; Kazunobu Sugawara; Tomonori Tateishi
Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.
Journal of clinical pharmacology 2005;45(6):690-4.
2005: Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Chirality 2005;17(6):338-44.
2005: S Kondo; Takashi Fukasawa; Norio Yasui-Furukori; Toshiaki Aoshima; Akihito Suzuki; Y Inoue; Tomonori Tateishi; Koichi Otani
Induction of the metabolism of etizolam by carbamazepine in humans.
European journal of clinical pharmacology 2005;61(3):185-8.
2005: Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
British journal of clinical pharmacology 2005;59(3):302-9.
2005: Tsukasa Uno; Norio Yasui-Furukori; Takenori Takahata; Kazunobu Sugawara; Tomonori Tateishi
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;816(1-2):309-14.
2005: Norio Yasui-Furukori; Yoshimasa Inoue; Sunao Kaneko; Koichi Otani
Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis 2005;37(1):121-5.
2005: Taku Nakagami; Norio Yasui-Furukori; Manabu Saito; Kazuo Mihara; Ronald De Vries; Tsuyoshi Kondo; Sunao Kaneko
Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.
Journal of clinical psychopharmacology 2005;25(1):89-91.
2005: Takenori Takahata; Norio Yasui-Furukori; Juichi Sakamoto; Koji Suto; Toshiyuki Suto; Tomonori Tateishi; Akihiro Munakata
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker.
Drugs in R&D 2005;6(6):385-94.
2005: Yukio Ishizawa; Norio Yasui-Furukori; Takenori Takahata; Mutsuo Sasaki; Tomonori Tateishi
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Clinical pharmacokinetics 2005;44(11):1179-89.
2005: Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Clinical pharmacology and therapeutics 2005;77(1):17-23.
2004: Norio Yasui-Furukori; Yoshimasa Inoue; Tomonori Tateishi
Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):153-7.
2004: Yukihiro Hasegawa; Shingo Takanashi; Koichi Okudera; Masahiko Aoki; Kiyoshi Basaki; Hidehiro Kondo; Takenori Takahata; Norio Yasui-Furukori; Tomonori Tateishi; Yoshinao Abe; Ken Okumura
Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
Japanese journal of clinical oncology 2004;34(11):647-53.
2004: Norio Yasui-Furukori; Masato Saito; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Tomonori Tateishi
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Journal of clinical pharmacology 2004;44(11):1223-9.
2004: Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
European journal of clinical pharmacology 2004;60(9):623-8.
2004: Takashi Fukasawa; Norio Yasui-Furukori; Toshiaki Aoshima; Akihito Suzuki; Tomonori Tateishi; Koichi Otani
Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.
Therapeutic drug monitoring 2004;26(5):529-33.
2004: Norio Yasui-Furukori; Hanako Furukori; Taku Nakagami; Manabu Saito; Yoshimasa Inoue; Sunao Kaneko; Tomonori Tateishi
Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response.
Therapeutic drug monitoring 2004;26(4):361-5.
2004: K Araki; Norio Yasui-Furukori; Takashi Fukasawa; Toshiaki Aoshima; Akihito Suzuki; Y Inoue; Tomonori Tateishi; Koichi Otani
Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.
European journal of clinical pharmacology 2004;60(6):427-30.
2004: Tsukasa Uno; Norio Yasui-Furukori; Takenori Takahata; Kazunobu Sugawara; Tomonori Tateishi
Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 2004;35(4):937-42.
2004: Norio Yasui-Furukori; Yoshimasa Inoue; Misturu Chiba; Tomonori Tateishi
Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):175-80.
2004: Norio Yasui-Furukori; Manabu Saito; Hanako Furukori; Yoshimasa Inoue; Toshiyuki Someya; Sunao Kaneko; Tomonori Tateishi
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
Therapeutic drug monitoring 2004;26(3):336-41.
2004: Takenori Takahata; Norio Yasui-Furukori; Gen Yoshiya; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.
Basic & clinical pharmacology & toxicology 2004;94(5):252-6.
2004: Norio Yasui-Furukori; Hanako Furukori; Ayako Kaneda; Sunao Kaneko; Tomonori Tateishi
The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil.
Journal of clinical pharmacology 2004;44(5):538-42.
2004: Norio Yasui-Furukori; Kazuo Mihara; Takenori Takahata; Akihito Suzuki; Taku Nakagami; Ronald De Vries; Tomonori Tateishi; Tsuyoshi Kondo; Sunao Kaneko
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
British journal of clinical pharmacology 2004;57(5):569-75.
2004: Norio Yasui-Furukori; Takenori Takahata; Taku Nakagami; Gen Yoshiya; Yoshimasa Inoue; Sunao Kaneko; Tomonori Tateishi
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
British journal of clinical pharmacology 2004;57(4):487-94.
2004: Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Yoshimasa Inoue; Sunao Kaneko
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
Psychopharmacology 2004;171(2):223-7.
2003: Norio Yasui-Furukori; Hanako Furukori; Manabu Saito; Yoshimasa Inoue; Sunao Kaneko; Tomonori Tateishi
Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.
Therapeutic drug monitoring 2003;25(6):709-14.
2003: Hideto Kanda; Norio Yasui-Furukori; Takashi Fukasawa; Toshiaki Aoshima; Akihito Suzuki; Koichi Otani
Interaction study between fluvoxamine and quazepam.
Journal of clinical pharmacology 2003;43(12):1392-7.
2003: Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Akihito Suzuki; Yoshimasa Inoue; Sunao Kaneko
Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
Journal of clinical psychopharmacology 2003;23(5):435-40.
2003: Karin Herrlin; Norio Yasui-Furukori; Gunnel Tybring; Jolanta Widén; Lars ´Gustafsson; Leif Bertilsson
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.
British journal of clinical pharmacology 2003;56(4):415-21.
2003: Tsuyoshi Kondo; Kazuo Mihara; Akihito Suzuki; Norio Yasui-Furukori; Sunao Kaneko
Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(6):921-6.
2003: Kimiyasu Kato; Norio Yasui-Furukori; Takashi Fukasawa; Toshiaki Aoshima; Akihito Suzuki; Muneaki Kanno; Koichi Otani
Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.
Therapeutic drug monitoring 2003;25(4):473-7.
2003: Norio Yasui-Furukori; Yoshimasa Inoue; Tomonori Tateishi
Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;789(2):239-45.
2003: Kazuo Mihara; Tsuyoshi Kondo; Norio Yasui-Furukori; Akihito Suzuki; Masayuki Ishida; Shingo Ono; Takahiro Kubota; Tatsuji Iga; Yutaka Takarada; Ronald de Vries; Sunao Kaneko
Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Therapeutic drug monitoring 2003;25(3):287-93.
2003: Takenori Takahata; Norio Yasui-Furukori; Shingo Sasaki; Tomonori Igarashi; Ken Okumura; Akihiro Munakata; Tomonori Tateishi
Nucleotide changes in the translated region of SCN5A from Japanese patients with Brugada syndrome and control subjects.
Life sciences 2003;72(21):2391-9.
2003: Norio Yasui-Furukori; Takenori Takahata; Tsuyoshi Kondo; Kazuo Mihara; Sunao Kaneko; Tomonori Tateishi
Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.
British journal of clinical pharmacology 2003;55(4):382-8.
2003: Akihito Suzuki; Norio Yasui-Furukori; Kazuo Mihara; Tsuyoshi Kondo; Hanako Furukori; Yoshimasa Inoue; Sunao Kaneko; Koichi Otani
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Therapeutic drug monitoring 2003;25(2):192-6.
2003: Norio Yasui-Furukori; Kazuo Mihara; Tsuyoshi Kondo; Takahiro Kubota; Tatsuji Iga; Yutaka Takarada; Ronald De Vries; Sunao Kaneko; Tomonori Tateishi
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Journal of clinical pharmacology 2003;43(2):122-7.
2003: Kazuo Mihara; Tsuyoshi Kondo; Akihito Suzuki; Norio Yasui-Furukori; Shingo Ono; Akira Sano; Kazuko Koshiro; Koichi Otani; Sunao Kaneko
Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2003;117B(1):57-60.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Takenori Takahata; Kazuo Mihara; Shingo Ono; Sunao Kaneko; Tomonori Tateishi
Effect of dietary fat content in meals on pharmacokinetics of quazepam.
Journal of clinical pharmacology 2002;42(12):1335-40.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Akihito Suzuki; Yoshimasa Inoue; Ronald De Vries; Sunao Kaneko
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Journal of clinical pharmacology 2002;42(10):1083-8.
2002: Kazuo Mihara; Norio Yasui-Furukori; Tsuyoshi Kondo; Masayuki Ishida; Shingo Ono; Tadashi Ohkubo; Takako Osanai; Kazunobu Sugawara; Koichi Otani; Sunao Kaneko
Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.
Therapeutic drug monitoring 2002;24(4):563-6.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Akihito Suzuki; Kazuo Mihara; Sunao Kaneko
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Psychopharmacology 2002;162(1):63-6.
2002: Shingo Ono; Kazuo Mihara; Akihito Suzuki; Tsuyoshi Kondo; Norio Yasui-Furukori; Hanako Furukori; Ronald de Vries; Sunao Kaneko
Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Psychopharmacology 2002;162(1):50-4.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Akihito Suzuki; Kazuo Mihara; Sunao Kaneko; Koichi Otani
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Progress in neuro-psychopharmacology & biological psychiatry 2002;26(3):575-8.
2002: Norio Yasui-Furukori; Rie Furuya; Takenori Takahata; Tomonori Tateishi
Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;768(2):261-5.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Masayuki Ishida; Osamu Tanaka; Kazuo Mihara; Sunao Kaneko; Koichi Otani
The characteristics of side-effects of bromperidol in schizophrenic patients.
Psychiatry and clinical neurosciences 2002;56(1):103-6.
2002: Tsuyoshi Kondo; Masayuki Ishida; Noboru Tokinaga; Kazuo Mihara; Norio Yasui-Furukori; Shingo Ono; Sunao Kaneko
Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin.
Progress in neuro-psychopharmacology & biological psychiatry 2002;26(2):287-91.
2002: Norio Yasui-Furukori; Tsuyoshi Kondo; Masayuki Ishida; Hanako Furukori; Akihito Suzuki; Sunao Kaneko; Masayoshi Inoue; Koichi Otani
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
Progress in neuro-psychopharmacology & biological psychiatry 2002;26(1):53-7.
2002: Norio Yasui-Furukori; Tomonori Tateishi
Carbamazepine decreases antihypertensive effect of nilvadipine.
Journal of clinical pharmacology 2002;42(1):100-3.
2001: Norio Yasui-Furukori; Tsuyoshi Kondo; Akihito Suzuki; Kazuo Mihara; Noboru Tokinaga; Yoshimasa Inoue; Koichi Otani; Sunao Kaneko
Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.
Schizophrenia research 2001;52(1-2):139-42.
2001: Akihito Suzuki; Tsuyoshi Kondo; Koichi Otani; Kazuo Mihara; Norio Yasui-Furukori; A Sano; K Koshiro; Sunao Kaneko
Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome.
The American journal of psychiatry 2001;158(10):1714-6.
2001: Akihito Suzuki; Tsuyoshi Kondo; Kazuo Mihara; Norio Yasui-Furukori; Masayuki Ishida; Hanako Furukori; Sunao Kaneko; Yoshimasa Inoue; Koichi Otani
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Pharmacogenetics 2001;11(6):545-50.
2001: Norio Yasui-Furukori; T Kondo; T Kubota; H Otake; T Ohkubo; T Nagasaki; Kazunobu Sugawara; K Chiba; K Otani; Sunao Kaneko
No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam.
European journal of clinical pharmacology 2001;57(4):285-8.
2001: Kazuo Mihara; Tsuyoshi Kondo; Akihito Suzuki; Norio Yasui-Furukori; Shingo Ono; Koichi Otani; Sunao Kaneko
Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.
Pharmacology & toxicology 2001;88(5):267-70.
2001: Kazuo Mihara; Akihito Suzuki; Tsuyoshi Kondo; Norio Yasui-Furukori; Shingo Ono; Koichi Otani; Sunao Kaneko; Y Inoue
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
American journal of medical genetics 2001;105(3):271-4.
2001: Akihito Suzuki; Tsuyoshi Kondo; Kazuo Mihara; Norio Yasui-Furukori; Koichi Otani; Hanako Furukori; Sunao Kaneko; Y Inoue
Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
European archives of psychiatry and clinical neuroscience 2001;251(2):57-9.